63 related articles for article (PubMed ID: 24248544)
1. CXCL12 rs1801157 polymorphism in patients with breast cancer, Hodgkin's lymphoma, and non-Hodgkin's lymphoma.
de Oliveira KB; Oda JM; Voltarelli JC; Nasser TF; Ono MA; Fujita TC; Matsuo T; Watanabe MA
J Clin Lab Anal; 2009; 23(6):387-93. PubMed ID: 19927352
[TBL] [Abstract][Full Text] [Related]
2. Association of the rs1966265 and rs351855
Carrillo-Dávila IA; Garibaldi-Ríos AF; Figuera LE; Gómez-Meda BC; Zúñiga-González GM; Puebla-Pérez AM; García-Verdín PM; Castro-García PB; Gutiérrez-Hurtado IA; Torres-Mendoza BM; Gallegos-Arreola MP
Biomedicines; 2024 Mar; 12(3):. PubMed ID: 38540215
[TBL] [Abstract][Full Text] [Related]
3. Association of LIN28B Gene Polymorphisms (rs221634, rs221635, rs314276, rs9404590, and rs12194974) with Non-Hodgkin Lymphoma Susceptibility and Clinical/Pathological Features.
Aghighi A; Nakhaee A; Taheri M; Hashemi SM; Bahari G
Asian Pac J Cancer Prev; 2023 Nov; 24(11):3867-3874. PubMed ID: 38019245
[TBL] [Abstract][Full Text] [Related]
4.
Kim JH; Jeong SY; Jang HJ; Park ST; Kim HS
Front Oncol; 2021; 11():762528. PubMed ID: 34737965
[TBL] [Abstract][Full Text] [Related]
5. Effects of FGFR4 G388R, V10I polymorphisms on the likelihood of cancer.
Peng T; Sun Y; Lv Z; Zhang Z; Su Q; Wu H; Zhang W; Yuan W; Zuo L; Shi L; Zhang LF; Zhou X; Mi Y
Sci Rep; 2021 Jan; 11(1):1373. PubMed ID: 33446698
[TBL] [Abstract][Full Text] [Related]
6. Fibroblast growth factor receptor 4 single nucleotide polymorphism Gly388Arg in head and neck carcinomas.
Wimmer E; Ihrler S; Gires O; Streit S; Issing W; Bergmann C
World J Clin Oncol; 2019 Mar; 10(3):136-148. PubMed ID: 30949443
[TBL] [Abstract][Full Text] [Related]
7. Functional FGFR4 Gly388Arg polymorphism contributes to oral squamous cell carcinoma susceptibility.
Chou CH; Hsieh MJ; Chuang CY; Lin JT; Yeh CM; Tseng PY; Yang SF; Chen MK; Lin CW
Oncotarget; 2017 Nov; 8(56):96225-96238. PubMed ID: 29221201
[TBL] [Abstract][Full Text] [Related]
8. Functional FGFR4 Gly388Arg polymorphism contributes to cancer susceptibility: Evidence from meta-analysis.
Xiong SW; Ma J; Feng F; Fu W; Shu SR; Ma T; Wu C; Liu GC; Zhu J
Oncotarget; 2017 Apr; 8(15):25300-25309. PubMed ID: 28445975
[TBL] [Abstract][Full Text] [Related]
9. Polymorphism in interleukin 21 gene is associated with decreased susceptibility to diffuse large B cell lymphoma.
Li J; Mai J
Tumour Biol; 2014 Nov; 35(11):11295-300. PubMed ID: 25117075
[TBL] [Abstract][Full Text] [Related]
10. Association between fibroblast growth factor receptor 4 Gly388Arg polymorphism and ischaemic stroke.
Zhang HF; Zhao KJ; Yang PF; Fang YB; Zhang YH; Liu JM; Huang QH
J Int Med Res; 2012; 40(5):1708-14. PubMed ID: 23206452
[TBL] [Abstract][Full Text] [Related]
11. An updated meta-analysis of the association between fibroblast growth factor receptor 4 polymorphisms and susceptibility to cancer.
Moazeni-Roodi A; Sarabandi S; Karami S; Hashemi M; Ghavami S
Biosci Rep; 2020 Oct; 40(10):. PubMed ID: 33017009
[TBL] [Abstract][Full Text] [Related]
12. FGFR4 transmembrane domain polymorphism and cancer risk: a meta-analysis including 8555 subjects.
Xu W; Li Y; Wang X; Chen B; Wang Y; Liu S; Xu J; Zhao W; Wu J
Eur J Cancer; 2010 Dec; 46(18):3332-8. PubMed ID: 20638838
[TBL] [Abstract][Full Text] [Related]
13. Fibroblast growth factor receptor 4 polymorphism is associated with increased risk and poor prognosis of non-Hodgkin's lymphoma.
Gao L; Feng Z; Li Q; Li L; Chen L; Xiao T
Tumour Biol; 2014 Apr; 35(4):2997-3002. PubMed ID: 24248544
[TBL] [Abstract][Full Text] [Related]
14. Fibroblast growth factor receptor 4 polymorphisms and the prognosis of non-Hodgkin lymphoma.
Cha Z; Zang Y; Guo H; Gu H; Tu X; Song H; Qian B
Mol Biol Rep; 2014 Feb; 41(2):1165-70. PubMed ID: 24381107
[TBL] [Abstract][Full Text] [Related]
15. Fibroblast growth factor receptor 4 polymorphisms and coronary artery disease: a case control study.
Zhu Q; Liu T
Mol Biol Rep; 2012 Sep; 39(9):8679-85. PubMed ID: 22696188
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]